Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
(R)-ketamine nasal spray in treatment-resistant depression: brain mechanism study
ChiCTR2500104532Phase 2Not yet recruiting
- Sponsor
- Beijing Anding Hospital
- Start
- Jun 2025
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Placebo group with (R)-ketamine hydrochloride nasal spray group (2 arms). Primary endpoints: Resting state functional magnetic resonance imaging, Natural stimulus task-state functional magnetic resonance imaging and 4 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
r-ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2500104532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104532.